Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2021 · 10-Q
Revenue$141.33M$141.33M+11.5% vs Q2 2020 Net Income$23.73M$23.73M−31.6% vs Q2 2020 EPS Diluted$0.43$0.43−33.8% vs Q2 2020 Operating Income$34,113,000−25.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$46,274,000−49.4% Margins · derivedOperating margin24.1%−11.8 pt vs Q2 2020
Net margin16.8%−10.6 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 6, 2021 · 37 d after period end